Investors welcome Mesoblast update and pathway for resubmission to FDA

“We thank the agency for their collaborative approach. The responses and guidance from FDA are clear and provide us with a high level of confidence to refile our BLA for remestemcel-L in children with SRaGVHD,” said Mesoblast CEO Dr Silviu Itescu. …